Diabetes Clinical Trials in Los Angeles

Showing 401-420 of 482 trials

The CareFUL Prevention Trial

NCT00803608

To assess the efficacy of TrueContour® Insoles versus the current standard of care insoles in recurrence of plantar MTH ulcers in men and women, 18 years of age or older at the time of consent with clinical diagnosis of Diabetes Mellitus type 1 or type 2 who have had at least one recently healed plantar MTH foot ulcer (\>1 week but \<12 weeks since heeling) and have Loss of Protective Sensation.

Plantar UlcerDiabetesNeuropathy Causing Loss of Protective Sensation

DIApedia, LLC130 participantsStarted Feb 2009

Phoenix, Arizona, United States • Tucson, Arizona, United States • Castro Valley, California, United States +8 more locations

COMPLETEDPhase 4< 1 mile

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

NCT01107886

The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications

Type 2 Diabetes Mellitus

AstraZeneca18,206 participantsStarted May 2010

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tempe, Arizona, United States +533 more locations

The CareFUL Prevention Trial

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Diabetes Trials in Other Cities

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Dapagliflozin DPPIV Inhibitor add-on Study

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

Markers and Mechanisms of Vascular Disease in Type II Diabetes

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Other Conditions in Los Angeles